Novo Nordisk A/S Statistics
Share Statistics
Novo Nordisk A/S has 4.44B
shares outstanding. The number of shares has increased by 0.11%
in one year.
| Shares Outstanding | 4.44B |
| Shares Change (YoY) | 0.11% |
| Shares Change (QoQ) | 0.11% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 3.91M, so 0.09% of the outstanding
shares have been sold short.
| Short Interest | 3.91M |
| Short % of Shares Out | 0.09% |
| Short % of Float | 0.12% |
| Short Ratio (days to cover) | 10.61 |
Valuation Ratios
The PE ratio is 27.29 and the forward
PE ratio is null.
Novo Nordisk A/S's PEG ratio is
0.19.
| PE Ratio | 27.29 |
| Forward PE | n/a |
| PS Ratio | 9.49 |
| Forward PS | n/a |
| PB Ratio | 19.2 |
| P/FCF Ratio | 39.56 |
| PEG Ratio | 0.19 |
Financial Ratio HistoryEnterprise Valuation
Novo Nordisk A/S has an Enterprise Value (EV) of 2,842.7B.
| EV / Sales | 9.79 |
| EV / EBITDA | 20.69 |
| EV / EBIT | 23.5 |
| EV / FCF | 40.81 |
Financial Position
The company has a current ratio of 0.74,
with a Debt / Equity ratio of 0.72.
| Current Ratio | 0.74 |
| Quick Ratio | 0.55 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 0.75 |
| Debt / FCF | 1.48 |
| Interest Coverage | 78.26 |
Financial Efficiency
Return on Equity is 70.38% and Return on Invested Capital is 38.99%.
| Return on Equity | 70.38% |
| Return on Assets | 21.68% |
| Return on Invested Capital | 38.99% |
| Revenue Per Employee | $3,751,685.92 |
| Profits Per Employee | $1,304,653.39 |
| Employee Count | 77,406 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 1.09 |
Taxes
| Income Tax | 26.2B |
| Effective Tax Rate | 20.6% |
Stock Price Statistics
The stock price has increased by -49.5% in the
last 52 weeks. The beta is 0.21, so Novo Nordisk A/S's
price volatility has been higher than the market average.
| Beta | 0.21 |
| 52-Week Price Change | -49.5% |
| 50-Day Moving Average | 70.34 |
| 200-Day Moving Average | 99.5 |
| Relative Strength Index (RSI) | 51.33 |
| Average Volume (20 Days) | 145,591 |
Income Statement
In the last 12 months, Novo Nordisk A/S had revenue of 290.4B
and earned 100.99B
in profits. Earnings per share was 22.68.
| Revenue | 290.4B |
| Gross Profit | 245.88B |
| Operating Income | 128.34B |
| Net Income | 100.99B |
| EBITDA | 137.38B |
| EBIT | 128.83B |
| Earnings Per Share (EPS) | 22.68 |
Full Income StatementBalance Sheet
The company has 15.65B in cash and 102.79B in
debt, giving a net cash position of -87.13B.
| Cash & Cash Equivalents | 15.65B |
| Total Debt | 102.79B |
| Net Cash | -87.13B |
| Retained Earnings | 144.45B |
| Total Assets | 465.8B |
| Working Capital | -56.63B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 120.97B
and capital expenditures -51.31B, giving a free cash flow of 69.66B.
| Operating Cash Flow | 120.97B |
| Capital Expenditures | -51.31B |
| Free Cash Flow | 69.66B |
| FCF Per Share | 15.64 |
Full Cash Flow StatementMargins
Gross margin is 84.67%, with operating and profit margins of 44.19% and 34.78%.
| Gross Margin | 84.67% |
| Operating Margin | 44.19% |
| Pretax Margin | 43.8% |
| Profit Margin | 34.78% |
| EBITDA Margin | 47.31% |
| EBIT Margin | 44.19% |
| FCF Margin | 23.99% |
